Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Evaxion Biotech A/S is currently managing 3 pending office actions in the Biotechnology & Pharmaceuticals technology area. These 3 actions are assigned to 3 distinct examiners, meaning each examiner is responsible for a single matter. The prosecution is divided between 2 distinct art units, indicating that the company's biotech innovations fall into more than one technical category.
BRIAN J GANGLE is the busiest examiner with 1 pending action, which is the same volume handled by the other 2 distinct examiners. The distribution of 3 pending office actions across 2 distinct art units requires the company to navigate the specific requirements of two different departments. With 3 distinct examiners involved, the company must also manage three individual examination styles within the Biotechnology & Pharmaceuticals sector.
For a practitioner, the presence of 3 distinct examiners for 3 pending office actions means there is no examiner concentration to leverage. However, the use of only 2 distinct art units suggests that the technical scope of the filings is relatively contained. Managing these 3 pending actions requires a strategy that accounts for three individual examination styles while addressing the standards of 2 different art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (50%) |
| Double-patenting only | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GANGLE, BRIAN J | 1 | 76.8% | +14.6% |
| DENT, ALANA HARRIS | 1 | 44.1% | +32.2% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18999335 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae | GANGLE, BRIAN J | — |
| 17995601 | Neoepitope immunotherapy with APC targeting unit | DENT, ALANA HARRIS | — |
| Art Unit | Apps |
|---|---|
| 1645 | 1 |
| 1643 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18999335 | Proteins and nucleic acids useful in vaccines targeting Klebsiella pneumoniae | GANGLE, BRIAN J | 1645 | §112 | Non-Final OA | — | Pending | Dec 23, 2024 |
| 17995601 | Neoepitope immunotherapy with APC targeting unit | DENT, ALANA HARRIS | 1643 | DP | Final Rejection | — | Pending | Oct 06, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialEvaxion Biotech A/S has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Brian J Gangle has the most, with 1 of Evaxion Biotech A/S's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
